Treatment of Neurodevelopmental Disorders in Adulthood

Overview

Journal J Neurosci

Specialty Neurology

Date 2012 Oct 12

PMID 23055475

Citations 30

Authors

Eero Castren

Ype Elgersma

Lamberto Maffei

Randi Hagerman

Affiliations

Soon will be listed here.

Abstract

Brain development in neurodevelopmental disorders has been considered to comprise a sequence of critical periods, and abnormalities occurring during early development have been considered irreversible in adulthood. However, findings in mouse models of neurodevelopmental disorders, including fragile X, Rett syndrome, Down syndrome, and neurofibromatosis type I suggest that it is possible to reverse certain molecular, electrophysiological, and behavioral deficits associated with these disorders in adults by genetic or pharmacological manipulations. Furthermore, recent studies have suggested that critical period-like plasticity can be reactivated in the adult brain by environmental manipulations or by pharmacotherapy. These studies open up a tantalizing possibility that targeted pharmacological treatments in combination with regimes of training or rehabilitation might alleviate or reverse the symptoms of neurodevelopmental disorders even after the end of critical developmental periods. Even though translation from animal experimentation to clinical practice is challenging, these results suggest a rational basis for treatment of neurodevelopmental disorders in adulthood.

Citing Articles

PROs for RARE: protocol for development of a core patient reported outcome set for individuals with genetic intellectual disability.

van Silfhout N, van Muilekom M, van Karnebeek C, Haverman L, Van Eeghen A Orphanet J Rare Dis. 2024; 19(1):354.

PMID: 39334201 PMC: 11428331. DOI: 10.1186/s13023-024-03264-0.

Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability.

Muller A, van Silfhout N, den Hollander B, Kampman D, Bakkum L, Brands M Ther Adv Rare Dis. 2024; 5:26330040241245721.

PMID: 38681798 PMC: 11047260. DOI: 10.1177/26330040241245721.

Beyond Diagnosis: Preliminary Study of Impact on Children and Parents in Neurodevelopmental Disorders and Juvenile Idiopathic Arthritis-Associated Uveitis.

Palmieri R, Albano V, Guerriero S, Craig F, La Torre F, Filoni S Diagnostics (Basel). 2024; 14(3).

PMID: 38337791 PMC: 10855410. DOI: 10.3390/diagnostics14030275.

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders.

Lauffer M, van Roon-Mom W, Aartsma-Rus A Commun Med (Lond). 2024; 4(1):6.

PMID: 38182878 PMC: 10770028. DOI: 10.1038/s43856-023-00419-1.

Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome.

Mancini V, Maeder J, Bortolin K, Schneider M, Schaer M, Eliez S Transl Psychiatry. 2021; 11(1):336.

PMID: 34052829 PMC: 8164636. DOI: 10.1038/s41398-021-01456-x.

References

Heulens I, DHulst C, Van Dam D, De Deyn P, Kooy R . Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012; 229(1):244-9. DOI: 10.1016/j.bbr.2012.01.031. View

Cui Y, Costa R, Murphy G, Elgersma Y, Zhu Y, Gutmann D . Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell. 2008; 135(3):549-60. PMC: 2673196. DOI: 10.1016/j.cell.2008.09.060. View

Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett J, Maffei L . Reactivation of ocular dominance plasticity in the adult visual cortex. Science. 2002; 298(5596):1248-51. DOI: 10.1126/science.1072699. View

Bhakar A, Dolen G, Bear M . The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci. 2012; 35:417-43. PMC: 4327822. DOI: 10.1146/annurev-neuro-060909-153138. View

Mainardi M, Scabia G, Vottari T, Santini F, Pinchera A, Maffei L . A sensitive period for environmental regulation of eating behavior and leptin sensitivity. Proc Natl Acad Sci U S A. 2010; 107(38):16673-8. PMC: 2944733. DOI: 10.1073/pnas.0911832107. View

Utari A, Chonchaiya W, Rivera S, Schneider A, Hagerman R, Faradz S . Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil. 2010; 115(5):433-43. PMC: 4031088. DOI: 10.1352/1944-7558-115.5.433. View

Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J . De novo gene disruptions in children on the autistic spectrum. Neuron. 2012; 74(2):285-99. PMC: 3619976. DOI: 10.1016/j.neuron.2012.04.009. View

Normann C, Schmitz D, Furmaier A, Doing C, Bach M . Long-term plasticity of visually evoked potentials in humans is altered in major depression. Biol Psychiatry. 2007; 62(5):373-80. DOI: 10.1016/j.biopsych.2006.10.006. View

Auerbach B, Osterweil E, Bear M . Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011; 480(7375):63-8. PMC: 3228874. DOI: 10.1038/nature10658. View

10.

Krab L, Aarsen F, de Goede-Bolder A, Catsman-Berrevoets C, Arts W, Moll H . Impact of neurofibromatosis type 1 on school performance. J Child Neurol. 2008; 23(9):1002-10. DOI: 10.1177/0883073808316366. View

11.

Pizzorusso T, Medini P, Landi S, Baldini S, Berardi N, Maffei L . Structural and functional recovery from early monocular deprivation in adult rats. Proc Natl Acad Sci U S A. 2006; 103(22):8517-22. PMC: 1482523. DOI: 10.1073/pnas.0602657103. View

12.

Huber K, Gallagher S, Warren S, Bear M . Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002; 99(11):7746-50. PMC: 124340. DOI: 10.1073/pnas.122205699. View

13.

Berry-Kravis E, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K . Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012; 4(152):152ra127. DOI: 10.1126/scitranslmed.3004214. View

14.

Cancedda L, Putignano E, Sale A, Viegi A, Berardi N, Maffei L . Acceleration of visual system development by environmental enrichment. J Neurosci. 2004; 24(20):4840-8. PMC: 6729456. DOI: 10.1523/JNEUROSCI.0845-04.2004. View

15.

Gross C, Berry-Kravis E, Bassell G . Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. Neuropsychopharmacology. 2011; 37(1):178-95. PMC: 3238060. DOI: 10.1038/npp.2011.137. View

16.

Krueger D, Bear M . Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med. 2010; 62:411-29. PMC: 3100156. DOI: 10.1146/annurev-med-061109-134644. View

17.

Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell I . Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010; 10:91. PMC: 2958860. DOI: 10.1186/1471-2377-10-91. View

18.

Bavelier D, Levi D, Li R, Dan Y, Hensch T . Removing brakes on adult brain plasticity: from molecular to behavioral interventions. J Neurosci. 2010; 30(45):14964-71. PMC: 2992973. DOI: 10.1523/JNEUROSCI.4812-10.2010. View

19.

Michalon A, Sidorov M, Ballard T, Ozmen L, Spooren W, Wettstein J . Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012; 74(1):49-56. PMC: 8822597. DOI: 10.1016/j.neuron.2012.03.009. View

20.

Jorge R, Acion L, Moser D, Adams Jr H, Robinson R . Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010; 67(2):187-96. PMC: 3718472. DOI: 10.1001/archgenpsychiatry.2009.185. View